Case Study: Novo Nordisk advances pharma life cycle assessments with BSI PAS 2090 pilot

Novo Nordisk improves LCA comparability and carbon hotspot identification with BSI's PAS 2090 pilot

Novo Nordisk, a global pharmaceutical company, sought to enhance its existing lifecycle assessment (LCA) framework for its products. The company participated in a pilot program for the PAS 2090 standard to assess its potential for integration, working with the vendor BSI.

By piloting BSI's PAS 2090 standard, Novo Nordisk was able to successfully integrate it into its LCA framework. The solution from BSI improved comparability and transparency in their assessments and enhanced their ability to identify carbon hotspots.

Novo Nordisk